nach oben

Lasers in Medical Science

Erschienen in:

01.06.2017 | Original Article

Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning

verfasst von: N. Betrouni, S. Boukris, F. Benzaghou

Erschienen in: Lasers in Medical Science | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Vascular targeted photodynamic therapy (VTP) with WST11 is a novel non-thermal focal treatment for localized prostate cancer that has shown favorable and early efficacy results in previously published studies. In this work, we investigate the efficiency of automatic dosimetric treatment planning. An action model established in a previous study was used in an image-guided optimization scheme to define the personalized optimal light dose for each patient. The calculated light dose is expressed as the number of optical cylindrical fibers to be used, their positions according to an external insertion grid, and the lengths of their diffuser parts. Evaluation of the method was carried out on data collected from 17 patients enrolled in two multi-centric clinical trials. The protocol consisted of comparing the method-simulated necrosis to the result observed on day 7 MR enhanced images. The method performances showed that the final result can be estimated with an accuracy of 10%, corresponding to a margin of 3 mm. In addition, this process was compatible with clinical conditions in terms of calculation times. The overall process took less than 10 min. Different aspects of the VTP procedure were already defined and optimized. Personalized treatment planning definition remained as an issue needing further investigation. The method proposed herein completes the standardization of VTP and opens new pathways for the clinical development of the technique.

Nur mit Berechtigung zugänglich

Windahl T, Andersson SO, Lofgren L (1990) Photodynamic therapy of localised prostatic cancer. Lancet 336(8723):1139CrossRefPubMed

Zaak D, Sroka R, Hoppner M, Khoder W, Reich O, Tritschler S, Muschter R, Knuchel R, Hofstetter A (2003) Photodynamic therapy by means of 5-ALA induced PPIX in human prostate cancer—preliminary results. Med Laser Appli 18:91–95CrossRef

Moore CM, Nathan TR, Lees WR, Mosse CA, Freeman A, Emberton A, Bown SG (2006) Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer. Lasers Surg med 38:356–363CrossRefPubMed

Moore CM, Pendse D, Emberton M (2009) Photodynamic therapy for prostate cancer—a review of current status and future promise. Nat Clin Pract Urol 6(1):18–30CrossRefPubMed

Bozzini G, Colin P, Nevoux P, Villers A, Mordon S, Betrouni N (2013) Focal therapy of prostate cancer: energies and procedures. Urol Oncol: Semin Orig Investig 31(2):155–167CrossRef

Vakrat-Haglili Y, Weiner L, Brumfeld V, Brandis A, Salomon Y, McLlroy B, Wilson BC, Pawlak A, Rozanowska M, Sarna T, Scherz A (2005) The microenvironment effect on the generation of reactive oxygen species by pd-bacteriopheophorbide. J AmChem Soc 127:6487–6497CrossRef

Madar-Balakirski N, Tempel-Brami C, Kalchenko V, Brenner O, Varon D, Scherz A, Salomon Y (2010) Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad. PLoS One 5(4):e10282CrossRefPubMedPubMedCentral

Azzouzi, et al. (2016) Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Under press, The Lancet Oncology

Moore CA, Azzouzi A, Barrett E, Villers A, Muir GH, Barber NJ, Bott S, Trachtenberg J, Arumainayagam N, Gaillac B, Allen C, Schertz A, Emberton M (2015) Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy. BJU 116(6):888–896CrossRef

10.

Azzouzi A, Lebdai S, Benzaghou F, Stief C (2015) Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure. World J Urol 33(7):937–944CrossRefPubMedPubMedCentral

11.

Betrouni N, Lopes R, Puech P, Colin P, Mordon S (2011) A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11. Phys med Biol 56(15):4771–4783CrossRefPubMed

12.

Betrouni N, Colin P, Puech P, Villers A, Mordon S (2013) An image guided treatment platform for prostate cancer photodynamic therapy. Conf Proc IEEE Eng Med Biol Soc 370–373 Osaka, Japan

13.

Haider MA, Davidson SRH, Kale AV, Weersink RA, Evans AJ, Toi A, Gertner MR, Bogaards A, Wilson B, Chin JL, Elhilali M, Trachtenberg J (2007) Prostate gland: MR imaging appearence after vasculat targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology 244(1):196–204CrossRefPubMed

14.

Panteledis ML, Whitehurst C, Moore JV, King TA, Blacklock NJ (1997) Photodynamic therapy for localised prostatic cancer-light penetration in the human prostate-gland. J Urol 143(2):398–401CrossRef

15.

Chen Q, Wilson BC, Shetty SD, Patterson MS, Cerny JC, Hetzl FW (1997) Changes in in vivo optical properties and light distribution in normal canine prostate during photodynamic therapy. Radia Res 147(1):86–91CrossRef

16.

Zhu TC, Finaly JC, Hahn SM (2005) Determination of the distribution of light, optical properties, drug concentration and tissue oxygenation in vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. J PhotochemPhotobiol 79(3):231–241

17.

Weersink RA, Bogaards A, Gertner M, Davidson SRH, Zhang K, Netchev G, Trachtenberg J, Wilson BC (2005) Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photoynamic therapy of the prostate: clinical experience and practicalities. J Photochem Photobiol B:Biol 79(3):211–222CrossRef

18.

Svensson T, Andersson-Engels S, Einarsdottir M, Svanberg K (2007) In vivo optical characterization of human prostate tissue using near-infrared time-resolved spectroscopy. JBioMOptics 12(1):1–10

19.

Swartling J, Axelsson J, Ahlgren G, Kälkner KM, Nilsson S, Svanberg S, Svanberg K, Andersson-Engels S (2010) System for interstitial photodynamic therapy with online dosimetry: first clinical experiences of prostate cancer. J Biomed opt 15(5):058003CrossRefPubMed

20.

Azzouzi AR, Barret E, Bennet J, Moore C, Taneja S, Muir G, Villers A, Coleman J, Allen C, Scherz A, Emberton M (2015) TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. World J Urol 33(7):945–953CrossRefPubMedPubMedCentral

21.

Wilson BC, Whelan W, Davidson SRH, Weersink R, Sherar MD (2002) Treatment planning platform for photodynamic therapy: architecture, function and validation. ProcSPIE 4612(85):92

22.

Alschuler MD, Zhu TC, Li J, Hahn SM (2008) Optimized interstitial PDT prostate treatment planning with the Cimmino feasibility algorithm. Med Phys 32(12):3525–3536

23.

Du KL, Mick R, Busch TM, Zhu TC, Finlay JC, Yodh AG, Malkowicz SB, Smith D, Whittington R, Stripp D, Hahn SM (2006) Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg med 38:427–434CrossRefPubMed

24.

Johansson A, Axelsson J, Andersson-Engels S, Swartling J (2007) Realtime light dosimetry software tools for interstitial photodynamic therapy of the human prostate. Med Phys 34:4309–4321CrossRefPubMed

25.

SRH D, Weersink RA, Haider MA, Gertner MR, Bogaards A, Giewercer D, Scherz A, Sherar MD, Elhilali M, Chin JL, Trachtenberg J, Wilson BC (2009) Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer. PhysMedBiol 54:2293–2313

26.

Fenning MC, Brown DQ, Chapman JD (1994) Photodosimetry of interstitial light delivery to solid tumours. Med Phys 21:1149–1156CrossRefPubMed

27.

Vollet-Filho JD, Menezes PFC, Moriyama LT, Grecco C, Sibata C, Allison RR, Castro O, Silva E Jr, Bagnato VS (2009) Possibility for a full optical determination of photodynamic therapy outcome. J Appl Phys 105:102038-1–102038-7CrossRef

28.

Makni N, Puech P, Colin P, Azzouzi A, Mordon S, Betrouni N (2012) Elastic image registration for guiding focal laser ablation of prostate cancer: preliminary results. Comput Methods Prog Biomed 108(1):213–223CrossRef

Titel: Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning
verfasst von: N. Betrouni
S. Boukris
F. Benzaghou
Publikationsdatum: 01.06.2017
Verlag: Springer London
Erschienen in: Lasers in Medical Science / Ausgabe 6/2017
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI: https://doi.org/10.1007/s10103-017-2241-7

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning

Abstract

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Efficacy of low-level laser therapy in management of symptomatic oral lichen planus: a systematic review

Validation of a mathematical model for laser-induced thermotherapy in liver tissue

BMLA Abstracts 2017

Photodynamic therapy controls of Staphylococcus aureus intradermal infection in mice

Mesenchymal stromal cell and osteoblast responses to oxidized titanium surfaces pre-treated with λ = 808 nm GaAlAs diode laser or chlorhexidine: in vitro study

Preliminary study in a new protocol for the treatment of oral mucositis in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) and chemotherapy (CT)